Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
08:01am, Friday, 06'th Jun 2025
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
06:10pm, Thursday, 08'th May 2025
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.56 per share a year ago.
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:01pm, Thursday, 08'th May 2025
HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update.
HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE).
Celldex Therapeutics to Present at Upcoming Investor Conferences
08:01am, Tuesday, 04'th Mar 2025
HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
08:01am, Monday, 03'rd Mar 2025
- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin - - Phase 1 study in healthy volunteers ongoing -
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
06:31pm, Thursday, 27'th Feb 2025
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.57 per share a year ago.
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
04:01pm, Thursday, 27'th Feb 2025
HAMPTON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2024 and provided a corpor
Blueprint Medicines price target lowered by $11 at Wedbush, here's why
08:44am, Monday, 13'th Jan 2025
Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%)
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
08:01am, Thursday, 19'th Dec 2024
HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy vo
Celldex Therapeutics to Present at Upcoming Investor Conferences
04:01pm, Monday, 11'th Nov 2024
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
06:30pm, Wednesday, 06'th Nov 2024
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago.
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 06'th Nov 2024
HAMPTON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate updat
